PET/CT using 18F-FDOPA provides improved staging of carcinoid tumor patients in a Canadian setting

Nuclear Medicine Communications

Volumn 33, Issue 3, 2012, Pages 322-330

  Yakemchuk, Valerie N ^a,b   Jager, Pieter L ^a,b   Chirakal, Raman ^b   Reid, Robert ^d   Major, Pierre ^a,b,c   Gulenchyn, Karen Y ^a,b  

^a HAMILTON HEALTH SCIENCES   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c Juravinski Cancer Center   (Canada)

^d LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

6 18F fluoro 3,4 dihydroxyphenylalanine; carcinoid tumor; diagnostic accuracy; neuroendocrine tumors; positron emission tomography computed tomography

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; 6 FLUORODOPA F 18; CATECHOLAMINE; CHROMOGRANIN A; KI 67 ANTIGEN; PENTETREOTIDE; PENTETREOTIDE IN 111; SOMATOSTATIN RECEPTOR; DIAGNOSTIC AGENT; DOPA; DRUG DERIVATIVE; FLUORINE; SOMATOSTATIN;

ADULT; AGED; ARTICLE; CANADA; CANCER SCINTISCANNING; CARCINOID; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; INTESTINE CARCINOID; INTESTINE TUMOR; MALE; NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; WHOLE BODY CT; WHOLE BODY PET; WHOLE BODY SCINTISCANNING; COMPARATIVE STUDY; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; REPRODUCIBILITY; SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; CANADA; CARCINOID TUMOR; DIHYDROXYPHENYLALANINE; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; INTESTINAL NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SOMATOSTATIN; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84856112289     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32834f2603     Document Type: Article

References (36)

1. Solcia E, Kloppel G, Sobin LH. Histological typing of endocrine tumours, 2nd ed. Heidelberg: World Health Organization 2000.
2. Rindi G, Capella C, Solcia E. Introduction to a revised clinicopathological classification of neuroendocrine tumors of the gastroenteropancreatic tract. Q J Nucl Med 2000; 44: 13-21. (Pubitemid 30325950)
3. Maroun J, Kocha W, Kvols L, Bjarnason G, Chen E, Germond C, et al. Guidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group. Curr Oncol 2006; 13: 67-76.
4. Pearse AGE. The APUD cell concept and its implications in pathology. In: Sommers SC, editor. Pathology annual. New York: Appleton Century Crofts; 1974. pp. 27-41.
5. Oberg K. Management of neuroendocrine tumours. Ann Oncol 2004; 15 (Suppl 4): iv293-iv298. (Pubitemid 39585350)
6. Plockinger U, Rindi G, Arnold R, Eriksson B, Krenning EP, de Herder WW, et al. European Neuroendocrine Tumour Society. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 2004; 80: 394-424. (Pubitemid 40874886)
7. Kumbasar B, Kamel IR, Tekes A, Eng J, Fishman EK, Wahl RL. Imaging of neuroendocrine tumors: accuracy of helical CTversus SRS. Abdom Imaging 2004; 29: 696-702. (Pubitemid 39331706)
8. Kisker O, Weinel RJ, Geks J, Zacara F, Joseph K, Rothmund M. Value of somatostatin receptor scintigraphy for preoperative localization of carcinoids. World J Surg 1996; 20: 162-167. (Pubitemid 26069481)
9. Scherubl H, Bader M, Fett U, Hamm B, Schmidt-Gayk H, Koppenhagen K, et al. Somatostatin-receptor imaging of neuroendocrine gastroenteropancreatic tumors. Gastroenterology 1993; 105: 1705-1709. (Pubitemid 24002786)
10. Chiti A, Fanti S, Savelli G, Romeo A, Bellanova B, Rodar M, et al. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-enteropancreatic tumours. Eur J Nucl Med 1998; 25: 1396-1403. (Pubitemid 28464114)
11. King CMP, Reznek RH, Bomanji J, Ur E, Britton KE, Grossman AB, Besser GM. Imaging neuroendocrine tumours with radiolabelled somatostatin analogues and X-ray computed tomography: a comparative study. Clin Radiol 1993; 48: 386-391. (Pubitemid 23362572)
12. Shi W, Johnston CF, Buchanan KD, Ferguson WR, Laird JD, Crothers JG, McIlrath EM. Localization of neuroendocrine tumours with [111In] DTPAoctreotide scintigraphy (octreoscan): a comparative study with CT and MR imaging. QJM 1998; 91: 295-301. (Pubitemid 28161912)
13. Jager PL, Chirakal R, Marriott CJ, Brouwers AH, Koopmans KP, Gulenchyn KY. 6-L-18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications. J Nucl Med 2008; 49: 573-586. (Pubitemid 351520605)
14. Koopmans KP, de Vries EG, Kema IP, Elsinga PH, Neels OC, Sluiter WJ, et al. Staging of carcinoid tumours with 18F-FDOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol 2006; 7: 728-734. (Pubitemid 44283659)
15. Montravers F, Grahek D, Kerrou K, Ruszniewski P, de Beco V, Aide N, et al. Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors? J Nucl Med 2006; 47: 1455-1462. (Pubitemid 47544931)
16. Hoegerle S, Altehoefer C, Ghanem N, Koehler G, Waller CF, Scheruebl H, et al. Whole-body 18F FDOPA PET for detection of gastrointestinal carcinoid tumors. Radiology 2001; 220: 373-378.
17. Koopmans KP, Neels OC, Kema IP, Elsinga PH, Sluiter WJ, Vanghillewe K, et al. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol 2008; 26: 1489-1495.
18. Becherer A, Szabo M, Karanikas G, Wunderbaldinger P, Angelberger P, Raderer M, et al. Imaging of advanced neuroendocrine tumors with (18)FFDOPA PET. J Nucl Med 2004; 45: 1161-1167. (Pubitemid 47611661)
19. Gilbert JA, Bates LA, Ames MM. Elevated aromatic-L-amino acid decarboxylase in human carcinoid tumors. Biochem Pharmacol 1995; 50: 845-850.
20. Kema IP, de Vries EG, Slooff MJ, Biesma B, Muskiet FA. Serotonin, catecholamines, histamine, and their metabolites in urine, platelets, and tumor tissue of patients with carcinoid tumors. Clin Chem 1994; 40: 86-95. (Pubitemid 24050218)
21. Feldman JM, Moore JO. Biogenic amines in carcinoid tumors. Biog Amines 1989; 6: 247-252. (Pubitemid 19109813)
22. Garnett ES, Firnau G, Nahmias C. FDOPAmine visualized in the basal ganglia of living man. Nature 1983; 305: 137-138. (Pubitemid 14235666)
23. Montravers F, Kerrou K, Nataf V, Huchet V, Lotz JP, Ruszniewski P, et al. Impact of fluorodihydroxyphenylalanine-18F positron emission tomography on management of adult patients with documented or occult digestive endocrine tumors. J Clin Endocrinol Metab 2009; 94: 1295-1301.
24. Schiesser M, Veit-Haibach P, Muller MK, Weber M, Bauerfeind P, Hany T, Clavien PA. Value of combined 6-[18F]fluorodihydroxyphenylalanine PET/CT for imaging of neuroendocrine tumours. Br J Surg 2010; 97: 691-697.
25. Fiebrich HB, Brouwers AH, Links TP, de Vries EG. Images in cardiovascular medicine: myocardial metastases of carcinoid visualized by 18F-dihydroxy- phenylalanine positron emission tomography. Circulation 2008; 118: 1602-1604.
26. Morel O, Giraud P, Cahouet A, Lacoeuille F, Girault S. Visualization of cardiac metastasis from medullary thyroid carcinoma on F-18 FDOPA PET/ CT scan. Clin Nucl Med 2010; 35: 253-255.
27. Luster M, Karges W, Zeich K, Pauls S, Verburg FA, Dralle H, et al. Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid 2010; 20: 527-533.
28. Marzola MC, Pelizzo MR, Ferdeghini M, Toniato A, Massaro A, Ambrosini V, et al. Dual PET/CT with (18)F-FDOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: comparison with conventional imaging. Eur J Surg Oncol 2010; 36: 414-421.
29. Koopmans KP, de Groot JW, Plukker JT, de Vries EG, Kema IP, Sluiter WJ, et al. 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. J Nucl Med 2008; 49: 524-531. (Pubitemid 351520599)
30. Fottner C, Helisch A, Anlauf M, Rossmann H, Musholt TJ, Kreft A, et al. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extra-adrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression. J Clin Endocrinol Metab 2010; 95: 2800-2810.
31. Fiebrich HB, Brouwers AH, Kerstens MN, Pijl ME, Kema IP, de Jong JR, et al. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess. J Clin Endocrinol Metab 2009; 94: 3922-3930.
32. Zemskova MS, Gundabolu B, Sinaii N, Chen CC, Carrasquillo JA, Whatley M, et al. Utility of various functional and anatomic imaging modalities for detection of ectopic adrenocorticotropin-secreting tumors. J Clin Endocrinol Metab 2010; 95: 1207-1219.
33. Fiebrich HB, Brouwers AH, Koopmans KP, de Vries EG. Combining 6-fluoro-[18F]-L-dihydroxyphenylalanine and [18F]fluoro-2-deoxy-D-glucose positron emission tomography for distinction of non-carcinoid malignancies in carcinoid patients. Eur J Cancer 2009; 45: 2312-2315.
34. Otonkoski T, Nanto-Salonen K, Seppanen M, Veijola R, Huopio H, Hussain K, et al. Noninvasive diagnosis of focal hyperinsulinism of infancy with [18F]-FDOPA positron emission tomography. Diabetes 2006; 55: 13-18. (Pubitemid 43343294)
35. Putzer D, Gabriel M, Kendler D, Henninger B, Knoflach M, Kroiss A, et al. Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro- Ldihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients. Q J Nucl Med Mol Imaging 2010; 54: 68-75.
36. Ambrosini V, Tomassetti P, Castellucci P, Campana D, Montini G, Rubello D, et al. Comparison between 68Ga-DOTA-NOC and 18F-FDOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging 2008; 35: 1431-1438